S101: COMBINATION OF A LUSPATERCEPT-LIKE DRUG (RAP-GRL) AND TMPRSS6-ASO IS SUPERIOR TO EITHER DRUG ALONE FOR CORRECTING β-THALASSEMIA

S101: COMBINATION OF A LUSPATERCEPT-LIKE DRUG (RAP-GRL) AND TMPRSS6-ASO IS SUPERIOR TO EITHER DRUG ALONE FOR CORRECTING β-THALASSEMIA

Bibliographic Details
Main Authors:	A. Guerra, P. Demsko, S. Sinha, P. McVeigh, C. Castruccio Castracani, L. Breda, C. Casu, S. Rivella
Format:	Article
Language:	English
Published:	Wiley 2022-01-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000684

Similar Items

P1520: AN ACTIVIN RECEPTOR IIB LIGAND TRAP, IN COMBINATION WITH TMPRSS6 INDUCED IRON-RESTRICTION, IS A SUPERIOR TREATMENT FOR CORRECTING Β-THALASSEMIA IN MICE
by: A. Guerra, et al.
Published: (2022-06-01)

Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia
by: Carla Casu, et al.
Published: (2016-01-01)

Tmprss6-ASO as a tool for the treatment of Polycythemia Vera mice.
by: Carla Casu, et al.
Published: (2021-01-01)

Highlights on the Luspatercept Treatment in Thalassemia
by: Yesim Aydinok
Published: (2023-02-01)

LUSPATERCEPT – A TREATMENT FOR THALASSEMIA?
by: Taimoor Hassan
Published: (2021-09-01)

Luspatercept‐induced reduction in transfusion requirement in α‐thalassemia
by: Nicholas Jackson, et al.
Published: (2020-07-01)

Luspatercept for transfusion-dependent β-thalassemia: time to get real
by: Khaled M. Musallam, et al.
Published: (2023-08-01)

Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia
by: Antonio Piga, et al.
Published: (2022-12-01)

GENE THERAPY IN THALASSEMIA AND HEMOGLOBINOPATHIES
by: Laura Breda, et al.
Published: (2009-11-01)

Genetic loss of Tmprss6 alters terminal erythroid differentiation in a mouse model of β-thalassemia intermedia
by: David B. Stagg, et al.
Published: (2019-10-01)

RationalGRL: A framework for argumentation and goal modeling
by: Marc van Zee, et al.
Published: (2021-06-01)

Luspatercept in β‐thalassemia: Who and when. Strengths and weaknesses points of a real‐world evidence
by: Lorenza Torti, et al.
Published: (2024-12-01)

SUCCESSFUL REDUCTION OF TRANSFUSION DEPENDENCE WITH LUSPATERCEPT IN A PATIENT WITH THALASSEMIA MAJOR: A CASE REPORT
by: Gökhan Demirci, et al.
Published: (2024-12-01)

Optimization of luspatercept treatment for beta-thalassemia transmission control using pure fraction mathematical modeling
by: Sapna Ratan Shah
Published: (2025-01-01)

P1506: REAL-WORLD DATA ON THE USE OF LUSPATERCEPT IN GREEK PATIENTS WITH TRANSFUSION DEPENDENT THALASSEMIA
by: P. Delaporta, et al.
Published: (2022-06-01)

Luspatercept's use in a patient with transfusion‐dependent beta‐thalassemia and intrathoracic extramedullary hematopoiesis (EMH)
by: Mohammed Najdat Seijari, et al.
Published: (2024-05-01)

P1518: LONG-TERM SAFETY RESULTS OF THE BELIEVE STUDY OF LUSPATERCEPT IN ADULTS WITH ΒETA-THALASSEMIA
by: V. Viprakasit, et al.
Published: (2022-06-01)

Luspatercept: A New Tool for the Treatment of Anemia Related to β-Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis
by: Eleftheria Hatzimichael, et al.
Published: (2022-10-01)

Comprehensive review of adverse reactions and toxicology in ASO-based therapies for Duchenne Muscular Dystrophy: From FDA-approved drugs to peptide-conjugated ASO
by: Umme Sabrina Haque, et al.
Published: (2024-01-01)

Bridging User−Centered Design and Requirements Engineering with GRL and Persona Cases
by: Faily, S
Published: (2011)

GrlR, a negative regulator in enteropathogenic E. coli, also represses the expression of LEE virulence genes independently of its interaction with its cognate partner GrlA
by: Cristina Lara-Ochoa, et al.
Published: (2023-02-01)

P1466: EFFECT OF LUSPATERCEPT ON BONE MINERAL DENSITY IN PATIENTS WITH BETA‑THALASSEMIA ENROLLED IN THE PHASE 3 BELIEVE TRIAL
by: Thomas D. Coates, et al.
Published: (2023-08-01)

Maxilon Blue GRL Boyar Maddesinin İllit Kil Minerali İle Gideriminin Optimizasyonu
by: Elif Ozmetin, et al.
Published: (2022-01-01)

S270: LONGER-TERM ANALYSIS OF EFFICACY OF LUSPATERCEPT VERSUS PLACEBO IN PATIENTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA ENROLLED IN THE BELIEVE STUDY
by: M. D. Cappellini, et al.
Published: (2022-06-01)

Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy
by: Musallam KM, et al.
Published: (2023-05-01)

Luspatercept in patients with lower-risk myelodysplastic syndromes
by: Fenaux, P, et al.
Published: (2020)

SimGRL: a simple self-supervised graph representation learning framework via triplets
by: Da Huang, et al.
Published: (2023-02-01)

P1508: LUSPATERCEPT REDUCES THE BURDEN OF RED BLOOD CELL TRANSFUSION IN PATIENTS WITH BETA -THALASSEMIA AND COMORBIDITIES: THE EXPERIENCE OF A SINGLE THALASSEMIA AND SICKLE CELL UNIT IN A UNIVERSITY HOSPITAL
by: S. Delicou, et al.
Published: (2022-06-01)

NanoSIMS Imaging Reveals the Impact of Ligand-ASO Conjugate Stability on ASO Subcellular Distribution
by: Emma Kay, et al.
Published: (2022-02-01)

β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies
by: Stefano Rivella
Published: (2015-04-01)

Optimizing lentiviral genomic integrations to cure beta-thalassemia: The least required for success?
by: Stefano Rivella
Published: (2024-03-01)

Progress Report on ASO-S: 2022–2024
by: GAN Weiqun
Published: (2024-08-01)

Individualized ASO therapy for rare diseases
Published: (2023-02-01)

Impact on efficacy of target reduction of two FDA-approved ASO drugs by intracellular glucose levels in in vitro cell models
by: Le Tra Giang Nguyen, et al.
Published: (2025-03-01)

Syntax of either in either… or… sentences
by: Wu, Danfeng
Published: (2022)

S273: LONG-TERM ERYTHROID RESPONSE DATA FROM PATIENTS (PTS) WITH NON-TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA (NTDT) RECEIVING LUSPATERCEPT IN THE BEYOND TRIAL
by: Ali T. Taher, et al.
Published: (2023-08-01)

The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia
by: Julio Delgado, et al.
Published: (2021-08-01)

Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases
by: Xiangke Xin, et al.
Published: (2025-02-01)

VALUE OF EARLY LUSPATERCEPT USE IN LOWER-RISK MYELODYSPLASTIC SYNDROMES
by: D Valcárcel, et al.
Published: (2024-10-01)

Luspatercept: A peaceful revolution in the standard of care for myelodysplastic neoplasms
by: Francesca Vinchi, et al.
Published: (2024-03-01)